![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
Hyperuricemia and Gout: The Role of Losartan
1St. John's University College of Pharmacy and Health Sciences, Queens, New York.
The Senior Care Pharmacist
|August 24, 2023
Insights
Losartan, an angiotensin II receptor blocker, uniquely reduces uric acid levels. Clinical guidelines now recommend it for hypertensive patients with gout due to its uricosuric properties.
Area of Science:
- Nephrology
- Cardiology
- Rheumatology
Background:
- Hypertension management often involves medications that can affect uric acid levels.
- Elevated uric acid is a risk factor for gout and kidney disease.
- Angiotensin II receptor blockers (ARBs) are a class of antihypertensive drugs.
Purpose of the Study:
- To highlight the unique uricosuric effect of losartan.
- To support the use of losartan in hypertensive patients with gout.
Main Methods:
- Review of clinical guidelines and pharmacological data.
- Analysis of losartan's mechanism of action on uric acid excretion.
Main Results:
- Losartan is the sole ARB demonstrated to significantly decrease serum uric acid.
- Its uricosuric effect is a recognized clinical benefit.
Conclusions:
- Losartan offers a dual benefit for hypertensive patients with gout by controlling blood pressure and lowering uric acid.
- Clinical practice guidelines recommend losartan for this patient population owing to its uricosuric properties.
Abstract:
Losartan is the only angiotensin II receptor blocker that has shown to significantly lower uric acid levels. The addition of or switch to losartan as an antihypertensive agent for patients with gout is recommended by clinical guidelines because of its benefit as a uricosuric agent.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
780
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
780
01:16Antihypertensive Drugs: Action of Diuretics
812
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
812
01:25Antihypertensive Drugs: Direct Renin Inhibitors
680
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
680
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
690
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
690
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420